Bai Xusheng, Zhang Enke, Ye Hua, Nandakumar Vijayalakshmi, Wang Zhuo, Chen Lihong, Tang Chuanning, Li Jianhui, Li Huijin, Zhang Wei, Han Wei, Lou Feng, Zhang Dandan, Sun Hong, Dong Haichao, Zhang Guangchun, Liu Zhiyuan, Dong Zhishou, Guo Baishuai, Yan He, Yan Chaowei, Wang Lu, Su Ziyi, Li Yangyang, Jones Lindsey, Huang Xue F, Chen Si-Yi, Gao Jinglong
Central Laboratory, People's Hospital of Shan Xi Province, Xian, China.
San Valley Biotechnology Incorporated, Beijing, China.
PLoS One. 2014 Jun 11;9(6):e99306. doi: 10.1371/journal.pone.0099306. eCollection 2014.
Breast cancer is the most common malignancy and the leading cause of cancer deaths in women worldwide. While specific genetic mutations have been linked to 5-10% of breast cancer cases, other environmental and epigenetic factors influence the development and progression of the cancer. Since unique mutations patterns have been observed in individual cancer samples, identification and characterization of the distinctive breast cancer molecular profile is needed to develop more effective target therapies. Until recently, identifying genetic cancer mutations via personalized DNA sequencing was impractical and expensive. The recent technological advancements in next-generation DNA sequencing, such as the semiconductor-based Ion Torrent sequencing platform, has made DNA sequencing cost and time effective with more reliable results. Using the Ion Torrent Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes to identify genetic mutations in 105 human breast cancer samples. The sequencing analysis revealed missense mutations in PIK3CA, and TP53 genes in the breast cancer samples of various histologic types. Thus, this study demonstrates the necessity of sequencing individual human cancers in order to develop personalized drugs or combination therapies to effectively target individual, breast cancer-specific mutations.
乳腺癌是全球女性中最常见的恶性肿瘤,也是癌症死亡的主要原因。虽然特定的基因突变与5%-10%的乳腺癌病例有关,但其他环境和表观遗传因素也会影响癌症的发生和发展。由于在个体癌症样本中观察到独特的突变模式,因此需要识别和表征独特的乳腺癌分子特征,以开发更有效的靶向治疗方法。直到最近,通过个性化DNA测序识别癌症基因突变既不切实际又昂贵。新一代DNA测序技术的最新进展,如基于半导体的Ion Torrent测序平台,使DNA测序在成本和时间上更有效,结果也更可靠。我们使用Ion Torrent Ampliseq癌症检测板,对45个癌症相关基因的737个位点进行测序,以识别105个人类乳腺癌样本中的基因突变。测序分析揭示了不同组织学类型乳腺癌样本中PIK3CA和TP53基因的错义突变。因此,本研究证明了对个体人类癌症进行测序的必要性,以便开发个性化药物或联合疗法,有效地靶向个体乳腺癌特异性突变。